" class="no-js "lang="en-US"> Corbus Pharmaceuticals - Medtech Alert
Sunday, October 01, 2023
Corbus Pharmaceuticals | Pharmtech Focus

Corbus Pharmaceuticals

About Corbus Pharmaceuticals

Corbus Pharmaceuticals

Corbus is committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer. Corbus’ current pipeline includes small molecules that activate or inhibit the endocannabinoid system and anti-integrin monoclonal antibodies that block activation of TGFβ.

Related Story

Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA

March 7 2023

Corbus Pharmaceuticals, a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, […]

Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

December 7 2021

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced the appointment of Rachael Brake, […]